An Efficacy and Safety Study of DFN-02
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs DFN 02 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Dr Reddys Laboratories
- 28 Jun 2017 Results from this study published in an Aegis Therapeutics Media Release.
- 07 Jun 2017 Primary endpoint has been met. (Proportion of patients who are pain-free at 2 hours postdose in the first double-blind treatment period), as reported in a Promius Pharma media release.
- 07 Jun 2017 Results published in a Promius Pharma media release.